184 related articles for article (PubMed ID: 38179299)
21. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.
Neumann HP; Pawlu C; Peczkowska M; Bausch B; McWhinney SR; Muresan M; Buchta M; Franke G; Klisch J; Bley TA; Hoegerle S; Boedeker CC; Opocher G; Schipper J; Januszewicz A; Eng C;
JAMA; 2004 Aug; 292(8):943-51. PubMed ID: 15328326
[TBL] [Abstract][Full Text] [Related]
22. Genetic spectrum in a Canadian cohort of apparently sporadic pheochromocytomas and paragangliomas: New data on multigene panel retesting over time.
Parisien-La Salle S; Dumas N; Bédard K; Jolin J; Moramarco J; Lacroix A; Lévesque I; Burnichon N; Gimenez-Roqueplo AP; Bourdeau I
Clin Endocrinol (Oxf); 2022 Jun; 96(6):803-811. PubMed ID: 34750850
[TBL] [Abstract][Full Text] [Related]
23. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
[TBL] [Abstract][Full Text] [Related]
24. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
25. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
26. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
[TBL] [Abstract][Full Text] [Related]
27. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
[TBL] [Abstract][Full Text] [Related]
28. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
[TBL] [Abstract][Full Text] [Related]
29. The phenotype of
Niemeijer ND; Rijken JA; Eijkelenkamp K; van der Horst-Schrivers ANA; Kerstens MN; Tops CMJ; van Berkel A; Timmers HJLM; Kunst HPM; Leemans CR; Bisschop PH; Dreijerink KMA; van Dooren MF; Bayley JP; Pereira AM; Jansen JC; Hes FJ; Hensen EF; Corssmit EPM
Eur J Endocrinol; 2017 Aug; 177(2):115-125. PubMed ID: 28490599
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of a novel nomogram predicting pseudohypoxia type pheochromocytomas and paragangliomas.
Wang Y; Liu L; Chen D; Pang Y; Xu X; Liu J; Li M; Guan X
J Endocrinol Invest; 2023 Jul; 46(7):1361-1371. PubMed ID: 36508127
[TBL] [Abstract][Full Text] [Related]
31. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
33. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
[TBL] [Abstract][Full Text] [Related]
34. Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas.
Castelblanco E; Santacana M; Valls J; de Cubas A; Cascón A; Robledo M; Matias-Guiu X
Endocr Pathol; 2013 Dec; 24(4):199-205. PubMed ID: 24096807
[TBL] [Abstract][Full Text] [Related]
35. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
Baysal BE; Maher ER
Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
[TBL] [Abstract][Full Text] [Related]
36. Universal Germline Panel Testing for Individuals With Pheochromocytoma and Paraganglioma Produces High Diagnostic Yield.
Horton C; LaDuca H; Deckman A; Durda K; Jackson M; Richardson ME; Tian Y; Yussuf A; Jasperson K; Else T
J Clin Endocrinol Metab; 2022 Apr; 107(5):e1917-e1923. PubMed ID: 35026032
[TBL] [Abstract][Full Text] [Related]
37. SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis.
Su T; Yang Y; Jiang L; Xie J; Zhong X; Wu L; Jiang Y; Zhang C; Zhou W; Ye L; Ning G; Wang W
Front Endocrinol (Lausanne); 2023; 14():1121397. PubMed ID: 37008946
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents.
Jochmanova I; Abcede AMT; Guerrero RJS; Malong CLP; Wesley R; Huynh T; Gonzales MK; Wolf KI; Jha A; Knue M; Prodanov T; Nilubol N; Mercado-Asis LB; Stratakis CA; Pacak K
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1051-1063. PubMed ID: 32062700
[TBL] [Abstract][Full Text] [Related]
39. Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic Pheochromocytoma and Paraganglioma.
Wang Y; Chen D; Pang Y; Xu X; Guan X; Liu L
Front Endocrinol (Lausanne); 2022; 13():882906. PubMed ID: 35574028
[TBL] [Abstract][Full Text] [Related]
40. Novel germline mutations in the SDHB and SDHD genes in Japanese pheochromocytomas.
Isobe K; Minowada S; Tatsuno I; Suzukawa K; Nissato S; Nanmoku T; Hara H; Yashiro T; Kawakami Y; Takekoshi K
Horm Res; 2007; 68(2):68-71. PubMed ID: 17308434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
